The European Commission designates OptPA, the W253R/R275S tissue
plasminogen activator developed by Op2Lysis, as an orphan drug for the
treatment of non-traumatic spontaneous intracerebral hemorrhage.
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders
Sensorion annonce le recrutement du premier patient dansl’essai clinique de preuve de concept du SENS-401 pour la préservation de l’audition résiduelle suite à une implantation cochléaire